Chardan Capital Reaffirms Buy Rating for Bright Minds Biosciences (NASDAQ:DRUG)

Bright Minds Biosciences (NASDAQ:DRUG)‘s stock had its “buy” rating reaffirmed by equities research analysts at Chardan Capital in a research note issued to investors on Friday,Benzinga reports. They currently have a $80.00 price target on the stock. Chardan Capital’s target price points to a potential upside of 2.51% from the company’s previous close.

Other research analysts have also recently issued research reports about the stock. Wall Street Zen upgraded shares of Bright Minds Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, December 27th. Zacks Research cut Bright Minds Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 2nd. Cantor Fitzgerald restated an “overweight” rating on shares of Bright Minds Biosciences in a research report on Monday, December 1st. HC Wainwright reaffirmed a “buy” rating and set a $115.00 price target on shares of Bright Minds Biosciences in a research note on Tuesday. Finally, BTIG Research started coverage on Bright Minds Biosciences in a research report on Monday, September 8th. They issued a “buy” rating and a $72.00 price objective for the company. Seven analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $90.00.

Bright Minds Biosciences Trading Up 2.9%

Shares of NASDAQ DRUG opened at $78.04 on Friday. Bright Minds Biosciences has a 1-year low of $23.17 and a 1-year high of $97.75. The company has a 50-day moving average of $69.39 and a two-hundred day moving average of $51.08. The company has a market cap of $607.93 million, a PE ratio of -63.97 and a beta of -6.14.

Hedge Funds Weigh In On Bright Minds Biosciences

Several institutional investors have recently modified their holdings of DRUG. Russell Investments Group Ltd. acquired a new stake in shares of Bright Minds Biosciences in the 3rd quarter valued at approximately $58,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Bright Minds Biosciences during the second quarter valued at approximately $28,000. Gordian Capital Singapore Pte Ltd bought a new stake in Bright Minds Biosciences in the third quarter valued at approximately $73,000. JPMorgan Chase & Co. raised its holdings in Bright Minds Biosciences by 624.3% in the second quarter. JPMorgan Chase & Co. now owns 2,173 shares of the company’s stock worth $57,000 after purchasing an additional 1,873 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Bright Minds Biosciences in the second quarter worth $66,000. 40.52% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Bright Minds Biosciences

Here are the key news stories impacting Bright Minds Biosciences this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $115 price target, and materially boosted its FY2030 EPS forecast to $2.24 — a long‑term upside signal that likely supports investor optimism. HC Wainwright Reiterates “Buy” Rating for Bright Minds Biosciences (NASDAQ:DRUG)
• Positive Sentiment: The stock moved higher intraday (~4.2% gain reported) after the analyst activity; intraday volume was below average, suggesting the move is at least partly driven by sentiment around the research notes rather than heavy institutional flows. Bright Minds Biosciences Trading 4.2% Higher — Here’s What Happened
• Neutral Sentiment: HC Wainwright maintains an aggressive multi‑year view (targets extending through FY2030) that mixes deep near‑term losses with projected future profitability; that makes the research note a mixed catalyst — bullish for long‑term upside, but conditional on execution and clinical progress. MarketBeat DRUG coverage
• Negative Sentiment: HC Wainwright cut numerous near‑term EPS forecasts (Q1–Q4 2026 and FY2026–FY2029) — e.g., FY2026 down to ($6.94) and other quarterly estimates lowered — signaling larger expected losses/cash burn in the next several years. Those downward revisions increase execution and financing risk, which is a negative for short‑term valuation. HC Wainwright estimates (MarketBeat summary)

About Bright Minds Biosciences

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.